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Introduction
The clinical course of Behcet’s disease (BD) as a multi-
systemic disorder with a remitting-relapsing nature is
unsufficiently explored. As complete remission should
be aimed in all inflammatory diseases, we investigated
the frequency of complete remission in patients with BD
in routine practice.
Methods
In this retrospective study, 258 patients with BD (F/M:
130/128, mean age: 41.1±11,5 years) classified according
to ISG criteria were included. The demographic and
clinical data for active organ manifestations and treat-
ment protocols were evaluated, both for the current
visit and in the last month. Patients having at least one
of any disease manifestations were categorized as active.
Results
A total of 1757 visits of 258 patients were overviewed.
Mean visit number was 6,8± 2,7 (range:1-10) and mean
follow-up duration was 45.8±36.5 months (2-165). One
hundred twenty-five patients (48.4%) were of mucocuta-
neus type, whereas 133 patients (51.6%) had major
organ involvement. When all visits combined, 19.8-
43.9% of the patients were using immunosuppressives
(IS), whereas 35.3-59.3% was under non-IS therapies
such as colchicine or NSAIDs. There was also a group
of noncompliant patients (6.4-45%) without any treat-
ment in some visits. Patients were clinically active in
67.2% (n=1182) of the total visits (n=1757). Frequency
of clinical activity increased to 75.6% (68.1- 90.3) when
the month before the visit was also included. The major
cause of the activity was aphthous ulcers (39.4-63.2%)
with other mucocutaneous manifestations also com-
monly present (Genital ulcer: 3.5-27.1 %, erythema
nodosum: 8.2-22.5%, papulopustular lesions: 18.2-33.7%,
arthritis: 21.3-33.5%, uveitis: 0.5-8.5% and vascular invol-
vement: 2.5-10.8%). No difference was observed between
the frequency of activity of patients having ISs or non-
IS therapies.
Conclusion
Although complete remission is the current, primary
target in inflammatory rheumatological diseases such as
rheumatoid arthritis or vasculitides, it is fairly difficult
to achieve complete remission in BD with current thera-
peutic regimens. The reluctance of the clinicians to be
aggressive for some BD manifestations with low morbid-
ity, such as mucocutaneous lesions, might be influencing
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